AbbVie Inc. Reports Strong Q2 2026 Performance with Growth Across Key Portfolios
In its second-quarter earnings call, AbbVie reported strong performance driven by double-digit growth in SKYRIZI, RINVOQ, and the neuroscience portfolio, all exceeding a 20% increase. Management attributed this success to SKYRIZI's leadership in psoriasis due to durable skin clearance and superior efficacy compared to other mechanisms. The acquisition of Apogee Therapeutics is expected to strengthen AbbVie’s immunology pipeline with long-acting biologics for the late 2030s. Neuroscience outperformance was driven by market share gains in Vraylar and growth across migraine treatments like Botox, Ubrelvi, and Qlipta. In oncology, newer assets such as Elahere and Epkinly are partially offsetting declines from IMBRUVICA due to IRA pricing pressures and competition. AbbVie raised its full-year revenue guidance by $300 million, citing strong commercial momentum across key products like RINVOQ in vitiligo and alopecia areata. The Parkinson’s portfolio is expected to reach peak sales exceeding $5 billion with the anticipated launch of tevapadone.
Tickers: $ABBV
Topics: aesthetics immunology neuroscience oncology pharmaceuticals